The ASCO annual meeting, held in person for the first time since 2019 due to the COVID-19 pandemic, was held June 3-7 in Chicago.
ASCO – also accessible virtually through live or on-demand sessions – has provided an excellent platform for healthcare professionals (HCPs) to learn about the latest developments in oncology while reconnecting with their peers.
We used CREATION Pinpoint to isolate the voice of healthcare professionals online and explore the social media conversations they had globally during the conference.
The overall volume of conversations between healthcare professionals appeared comparable to ASCO’s all-virtual annual meeting in 2021, down about 2%, but still attracting a lot of attention with more than 26,000 posts on the social networks of healthcare professionals during the 5-day conference.
Focus HCP: Cancers of the lung, breast, intestine
Much of the conversation on social media has focused on ASCO’s main purpose – the publication and presentation of new clinical trial data in oncology.
The three most frequently discussed topics by healthcare professionals were lung cancer, breast cancer and bowel/colorectal cancer.
The DESTINY-Breast04 trial – which compared fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) with physician’s choice of treatment for HER2-low metastatic breast cancer – sparked the largest spike in conversation.
The findings caught the attention of many healthcare professionals, who called the results “unprecedented”, a “change in practice” and an “significant moment in the history of this disease”.
Medical professionals celebrated both the drug’s effectiveness – with researchers reporting a significant increase in survival – and its manageable safety profile.
Several trials on lung cancer have aroused the interest of health professionals.
These included the NADIM-2 trial, which evaluated neoadjuvant nivolumab (Opdivo, Bristol Myers Squibb) with chemotherapy for non-small cell lung cancer. The diet appeared to be associated with positive response rates, and healthcare professionals said it could become a new standard of care.
Healthcare professionals have also reacted to trials that have not shown as positive an outcome as expected, such as the randomized phase 3 trial SKYSCRAPER-02.
The trial evaluated the addition of tiragolumab (Genentech), a new immune checkpoint inhibitor, to atezolizumab, an anti-PD-L1 monoclonal antibody (Tecentriq, Genentech) and chemotherapy as first-line treatment extensive stage small cell lung cancer. Adding tiragolumab did not provide survival benefit.
Most discussed product: Trastuzumab deruxtecan
Not surprisingly given the success of the DESTINY-Breast04 trial, trastuzumab deruxtecan was the most frequently discussed product among healthcare professionals across ASCO.
The second most mentioned product was dostarlimab (Jemperli, GlaxoSmithKline), discussed in the context of a small phase 2 study in which all 16 evaluated patients with locally advanced rectal cancer deficient in mismatch repair achieved a clinically complete response to monotherapy.
The publication of the study in The New England Journal of Medicine was the most shared resource among healthcare professionals during ASCO.
Healthcare professionals were thrilled to see the effectiveness of dostarlimab in this area, with the oncologist To mark A. lewisdoctor, director of gastrointestinal oncology at Intermountain Healthcare, describing the result as “absolutely amazing”.
Nivolumab came third, with medical professionals talking about the product in numerous lung cancer studies, including NADIM-2.
Four health professionals lead the discussions
Four HCPs were particularly active on social media during ASCO, each posting more than 400 times during the meeting.
They were: Cristiane Decat Bergerot, PhD, director of the department of psycho-oncology at. CETTRO Cancer Research Hospital in Brazil and visiting researcher at City of Hope; Gilberto Lopes, MD, FASCO, MBA, Associate Director for Global Oncology and Acting Chief of the Division of Medical Oncology at the University of Miami Sylvester Comprehensive Cancer Center; Dipesh Uprety, MD, thoracic oncologist and assistant professor in the department of medical oncology at the Karmanos Cancer Institute; and Santhosh Ambika, MD, hematologist-oncologist at Cancer Care Specialists and Renown Health Oncology.
While post volume is only one metric related to HCP influence on social media, these individuals have been key in driving discussions among their peers and reacting to the data as they have been presented.
Each author displayed their own content preferences and digital behaviors throughout the conference.
Bergerot took a general approach to the conference, covering all types of cancer and often choosing to share abstracts from the ASCO program guide, while Uprety focused on the lung cancer aspects of the congress and preferred to give own reflections using images from the presentations.
Figure 4. Top products discussed by HCPs at ASCO 2022.
The following items were presented at the ASCO annual meeting; June 3-7, 2022; Chicago:
Cercek A, et al. Summary LBA5.
Modi S, et al. Summary LBA3.
Provencio-Pulla M, et al. Abstract 8501.
Rudin CM, et al. Abstract LBA8507.
For more information:
Creation Healthcare is a digital insights consultancy that provides research and analysis to inform healthcare strategy, communication and policymaking among some of the largest healthcare companies, government organizations and organizations. non-governmental organizations in the world.